Nasia Safdar
MD

  • Infectious Diseases
Nasia Safdar, MD

About

Nasia Safdar has been the Medical Director of Infection Control at UW Hospital and Clinics since 2009. She came to Wisconsin in 1997 for her residency and fellowship. She is board certified in infectious disease and she focuses on healthcare-associated infections, particularly in the acute care setting. Dr. Safdar believes that many health care-associated infections can be prevented with adherence to known best practices. As medical director for the department of infection prevention, her job is to lead the department in its mission of reducing healthcare-associated infections by identifying, testing and implementing interventions that have benefit for reducing health care associated infections (HAI).

She is an associate professor of infectious diseases at the University of Wisconsin School of Medicine and Public Health and the Associate Chief of Staff for Research at the William S. Middleton VA Hospital. Her research includes the evaluation of novel and innovative strategies for prevention of HAI. She is currently leading the fecal bacteriotherapy program at UW Hospital and is the principal investigator of a current ongoing VA-funded trial of probiotics for reducing HAI.

Languages spoken
  • English
University affiliation
  • Department of Medicine

Practice locations

Loading...
  • University Hospital - Infectious Disease
    • 600 Highland Ave. / Madison, WI
    • (608) 263-0946
    • Closed now
    •  
      View hours, services and more

Education & credentials

Board certifications
  • Infectious Diseases
Medical School
  • Aga Khan University Medical College, Karachi, Pakistan
Fellowships
  • University of Wisconsin Hospital and Clinics, Madison, WI
Residencies
  • University of Wisconsin Hospital and Clinics, Madison, WI
Internships
  • Sir Ganga Ram Hospital, Lahore, Pakistan

Research and publications

Dr. Safdar is interested in examining the efficacy of novel interventions to reduce healthcare-associated infection such as the use of probiotics for reducing colonization by methicillin-resistant _Staphylococcus aureus_ and _Clostridium difficile_and has ongoing trials in this area.